Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMedOpen access

Exosomes in trichology: A literature review.

Lee KWA., Sydorchuk O., Song JK., Lee SR., Yu E., Kim SH.

Randomized Controlled Trial on Hair Loss, Hair Regeneration, published in JPRAS Open (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
JPRAS Open (2025)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
41561359
PMCID
PMC12814429
DOI
10.1016/j.jpra.2025.11.011
Citations
2

Abstract (original English)

Background Exosomes, nano-sized extracellular vesicles derived from various cell types, have emerged as a promising therapeutic modality in trichology. These vesicles deliver bioactive molecules, such as growth factors, cytokines, and microRNAs, that regulate key cellular processes, including proliferation, differentiation, and signaling, which are critical for hair follicle regeneration. Aim This review synthesizes findings from preclinical and clinical studies published on the applications of exosomes for treating hair loss conditions such as androgenetic alopecia (AGA), alopecia areata (AA), and chemotherapy-induced alopecia (CIA). Methods A comprehensive literature search was conducted using databases including MEDLINE, PubMed and Ovid databases for relevant studies published on clinical trials, diagnosis and treatment. Some papers were further reviewed using a double-blinding approach, sample size, control usage, randomization usage and objective endpoint measurements. All studies were classified according to the Oxford Center for evidence-based medicine evidence hierarchy. Results Preclinical studies demonstrate that exosomes derived from mesenchymal stem cells (MSCs), adipose stem cells (ASCs), dermal papilla cells (DPCs) and plant sources enhance dermal papilla cell (DPC) proliferation, activate signaling pathways such as Wnt/β-catenin, VEGF, and PI3K/AKT, and promote t

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research